Pharmacokinetics of ICI D0490 in Mice
Author Information
Author(s): J.A. Calvete, D.R. Newell, C.J. Charlton, A.F. Wright
Primary Institution: The Cancer Research Unit, University of Newcastle upon Tyne
Hypothesis
The pharmacokinetic advantages of using a hindered disulphide linker and recombinant ricin A-chain in ICI D0490 have been achieved.
Conclusion
ICI D0490 has excellent in vivo stability and persistence, making it a promising candidate for clinical evaluation in colorectal cancer treatment.
Supporting Evidence
- ICI D0490 showed a long elimination phase half-life of 33 hours.
- Plasma levels of ICI D0490 were sustained at over 20 µg/ml for 8 hours after administration.
- Clearance of ICI D0490 from plasma was extremely slow at 34 µl/min/kg.
Takeaway
Researchers studied a new cancer treatment in mice and found it stays in the body for a long time, which could help fight cancer better.
Methodology
The pharmacokinetics of ICI D0490 were studied in mice using intravenous administration and measuring plasma concentrations over time with ELISA.
Limitations
The study was conducted in non-tumour bearing mice, which may not fully represent the pharmacokinetics in cancer patients.
Participant Demographics
Six 8-week-old female Balb/c mice were used.
Statistical Information
Confidence Interval
95% confidence limits for LDIO values were calculated.
Want to read the original?
Access the complete publication on the publisher's website